OptimizeRx Corporation — FY 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual report; the supplied filing text does not provide a standalone fourth-quarter income statement.
Business context
OptimizeRx provides digital health technology that connects life sciences companies with healthcare providers and patients through messaging, patient-support, and therapy-initiation solutions. Its strategy emphasizes expanding enterprise relationships, adding solutions, and growing recurring revenue. The company acquired substantially all of EvinceMed’s assets in April 2022 to broaden its specialty-medication access platform.
Financial results and liquidity
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | $62.45 million | $61.29 million |
| Gross profit / margin | $38.97 million / 62.4% | $35.64 million / 58.1% |
| Operating expenses | $51.26 million | $35.28 million |
| Operating income (loss) | $(12.29) million | $0.36 million |
| Net income (loss) | $(11.44) million; $(0.64) per diluted share | $0.38 million; $0.02 per diluted share |
| Net cash from operating activities | $10.65 million | $0.73 million |
Revenue rose about 2%. Gross margin improved chiefly from favorable solution and channel mix, including increased activity in lower-cost channels and higher-margin program-design services. Operating expenses rose about 45%; stock-based compensation increased to $15.75 million from $5.49 million, including $6.1 million related to a market-based award. Management cited growth-related hiring and investment as additional expense drivers.
At year-end, cash and cash equivalents were $18.21 million and short-term U.S. government and agency securities were $55.93 million. Current assets were $98.58 million and current liabilities $8.40 million, yielding working capital of $90.18 million and a 12-to-1 current ratio. Total liabilities were $8.54 million, including lease liabilities; the balance sheet reports no borrowing debt. Management said existing cash, short-term investments, and operating cash generation should fund operations and planned growth for at least 12 months; significant cash acquisitions could require additional financing.
Investing activities used $58.18 million, primarily the $55.93 million purchase of short-term investments and $2.0 million cash paid for EvinceMed. Financing activities used $18.95 million, including approximately $20.0 million of share repurchases, partly offset by option-exercise proceeds. Cash declined by $66.47 million, largely reflecting the investment purchases and buyback.
Changes, outlook, and notable items
- Net revenue retention fell to 90% from 127%; average revenue per top-20 pharmaceutical manufacturer declined to $2.14 million from $2.48 million. Management attributed weaker expansion and slower large or new customer implementations to macroeconomic pressures and longer sales cycles.
- The top five customers generated 39% of 2022 revenue. One customer represented 10.9%; the largest channel partner generated 31.8% of revenue, down from 53.9% in 2021. This remains meaningful customer and partner concentration.
- Minimum revenue-share commitments totaled $16.4 million for 2023–2025: $6.2 million in 2023, $5.2 million in 2024, and $5.0 million in 2025.
- The EvinceMed purchase price was $12.08 million, comprising $2.0 million cash, previously paid amounts, and 240,741 shares valued at $9.37 million. The acquisition added $4.15 million of technology assets and $7.93 million of goodwill.
- The company repurchased 1,214,398 shares in 2022 for approximately $20.0 million, at an average reported price of $16.49 per share. The repurchase authorization terminated on December 1, 2022.
- No quantitative revenue or earnings guidance is provided. Management noted pharmaceutical-marketing seasonality, with activity typically lowest in the first quarter and highest in the fourth, and identified inflation, interest rates, slower customer spending, and fewer U.S. drug approvals as potential headwinds.
- Management identified a material weakness in internal control over financial reporting: inadequate controls to ensure third-party service-organization data is complete and accurate. Disclosure controls were deemed ineffective at the reasonable-assurance level. Planned remediation includes obtaining SOC 1 Type 2 reports or conducting direct control assessments and substantive testing. The auditor gave an unqualified opinion on the financial statements but did not provide an opinion on internal controls.
- The auditor identified revenue recognition as a critical audit matter because of judgments over distinct performance obligations, delivery timing, and contract terms. The company reported no current legal proceedings or off-balance-sheet arrangements.
Important facts for investors to verify
- Whether revenue growth, retention, and customer expansion improve after the reported slowing of customer spending and longer sales cycles.
- Progress integrating EvinceMed and the commercial contribution of its platform, relative to the purchase price and acquired goodwill.
- Exposure to the largest customers and channel partners, including the durability of the 31.8% revenue share from the largest partner.
- Cash generation and liquidity after scheduled $16.4 million minimum partner payments, operating needs, and any future acquisitions.
- Remediation of the material weakness and whether the company can establish effective financial-reporting controls.
- The scale and ongoing impact of stock-based compensation, including remaining unrecognized compensation expense disclosed in the filing.